AstraZeneca has received a marketing authorization for the drug Imjudo which is a cancer medicine. It is used to treat: hepatocellular carcinoma (a type of liver cancer) and non-small cell lung cancer (NSCLC) that has metastasised (spread to other parts of the body) in adult patients who have not been treated before. The drug is used in combination with durvalumab, another cancer medicine.
Tremelimumab is a fully human monoclonal antibody and is designed to attach to and block CTLA-4, a protein that controls the activity of T cells, which are part of the immune system (the body’s natural defenses). Tremelimumab was approved for medical use in the United States in October 2022, and in the European Union in February 2023.